Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfreundschuh

Showing results (171-180 of 260) with videos related to

Pageof 26
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1992
Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphomaA Gause, W Jung, R Schmits, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's diseaseA Gause, K Verpoort, V Roschansky, et al.
Lancet (London, England)|March 10, 1984
Long-term remission in acute myelogenous leukaemiaT Büchner, D Urbanitz, B Emmerich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upH Tilly, U Vitolo, J Walewski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2009
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trialN Schoof, F von Bonin, S Zeynalova, et al.
Genes and Immunity|January 12, 2007
The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphomaD Kube, T-D Hua, M Klöss, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989
Bone marrow transplantation in the treatment of Hodgkin's lymphoma: problems, remaining challenges, and future prospectsJ O Armitage, M J Barnett, A M Carella, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 17, 1986
[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group]V Diehl, M Pfreundschuh, F E Hauser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)A Wunderlich, M Kloess, M Reiser, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 1, 1990
[Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)]S L Roth, E Dühmke, H Kirschner, et al.
Pageof 26

Showing results (171-180 of 260) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1992
Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphomaA Gause, W Jung, R Schmits, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 1991
The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's diseaseA Gause, K Verpoort, V Roschansky, et al.
Lancet (London, England)|March 10, 1984
Long-term remission in acute myelogenous leukaemiaT Büchner, D Urbanitz, B Emmerich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2012
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upH Tilly, U Vitolo, J Walewski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2009
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trialN Schoof, F von Bonin, S Zeynalova, et al.
Genes and Immunity|January 12, 2007
The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphomaD Kube, T-D Hua, M Klöss, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1989
Bone marrow transplantation in the treatment of Hodgkin's lymphoma: problems, remaining challenges, and future prospectsJ O Armitage, M J Barnett, A M Carella, et al.
Medizinische Klinik (Munich, Germany : 1983)|January 17, 1986
[Intermediate results of therapy studies HD1, HD2 and HD3 of the German Hodgkin Study Group]V Diehl, M Pfreundschuh, F E Hauser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)A Wunderlich, M Kloess, M Reiser, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|September 1, 1990
[Radiotherapeutic quality assurance in the Hodgkin's disease study HD4 supported by the BMFT (Bundesministerium für Forschung und Technologie)]S L Roth, E Dühmke, H Kirschner, et al.
Pageof 26